- InfuSystem press release ( NYSE: INFU ): Q2 GAAP EPS of -$0.01 in-line.
- Revenue of $27.04M (+8.9% Y/Y) misses by $0.93M .
- Gross margin was 55.1%, a decrease of 5.5% vs. prior year.
- “While the quarter was solid, we are experiencing headwinds in ramping some of our important new business initiatives. Early in the quarter, our Pain Management business was impacted by lingering COVID-related supply chain challenges preventing us from onboarding new accounts. Fortunately, we believe these issues to be largely behind us, as we obtained sufficient inventory during the quarter to resume new account starts. We finished June on a strong note, with record patient treatments and a growing pipeline of new business that will keep us busy through the rest of the year, hopefully setting the stage for a record second half in Pain Management.”
- The company is revising full-year 2022 revenue growth guidance to be in the range of 10% to 13% vs. consensus growth of 14.95% with AEBITDA margin (non-GAAP) guidance to be in the 20% to 21% range.
For further details see:
InfuSystem GAAP EPS of -$0.01 in-line, revenue of $27.04M misses by $0.93M